The Australian Competition and Consumer Commission will not oppose the acquisition of global pharmaceutical giant Bayer’s animal health business by competitor Elanco, after the company agreed to divest certain brands to allay competition concerns.
The Australian Competition and Consumer Commission will not oppose the acquisition of global pharmaceutical giant Bayer’s animal health business by competitor Elanco, after the company agreed to divest certain brands to allay competition concerns.
For information on rights and reprints, contact subscriptions@lawyerly.com.au